Therapy monitoring of skeletal metastases with whole-body diffusion MRI

摘要: Current methods of assessing tumor response at skeletal sites with metastatic disease use a combination imaging tests, serum and urine biochemical markers, symptoms assessment. These do not always enable the positive assessment therapeutic benefit to be made but instead provide an evaluation progression, which then guides therapy decisions in clinic. Functional techniques such as whole-body diffusion magnetic resonance (MRI) when combined anatomic other emerging "wet" biomarkers can improve classification patients bone disease. A range findings seen clinic depending on type duration treatment. Successful systemic is usually depicted by reductions signal intensity accompanied apparent coefficient (ADC) increases. Rarer patterns successful treatment include no changes accompanying increases ADC values (T2 shine-through pattern) or without value changes. Progressive results extent/intensity high b-value images variable Diffusion MRI criteria need developed tested prospective studies order address current, unmet clinical pharmaceutical needs for reliable measures J. Magn. Reson. Imaging 2014;39:1049-1078. (c) 2014 Wiley Periodicals, Inc.